MULTIVALENT: THE KEY TO NEXT GENERATION CANCER TREATMENT

We are focused on developing multivalent immuno-oncology drugs capable of regulating, not blocking, multiple molecular pathways, in order to kill different cancer cell sub-types as well as reboot the immune system, all while providing patients with good quality of life. Our lead drug candidate Aneustat™ represents an ideal non-toxic therapy for cancer.

- Jeff Dao, Co-CEO, Omnitura